An unknown private equity investor entered into a binding agreement to acquire 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. (NasdaqCM:CYTO) for CHF 2.04 million on November 17, 2023. Altamira Therapeutics will retain 49% of the company's share capital. Further, Altamira will be entitled to receive 25% of Medicas future licensing income. Medica will continue its operations under its current name and with current staff in collaboration with Altamira. The transaction is set to close on November 21, 2023, subject to customary closing conditions.

An unknown private equity investor acquired 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. (NasdaqCM:CYTO) on November 21, 2023. Alex Nikitine, Fabienne Limacher and team of Walder Wyss Ltd. acted as legal advisor to Altamira Therapeutics in this transaction.